2023-05-17 12:52:35 ET
- Bausch Health ( NYSE: BHC ) soared 40% amid a court ruling related to the company's patent suit vs Norwich Pharma over Xifaxan.
- A U.S. District Judge denied Norwich's Rule 60 (b) motion.
- "I do no think Defendant's request fits in comfortably with the requirements of Rule 60 (b) (5), and I do no think, even if it, that it could be resolved in the summary fashion that Defendant seems to think," the judge wrote in the opinion.
- Developing story ...
For further details see:
Bausch Health soars amid court ruling in patent dispute with Norwich Pharma